Marjani, M., Baghaei, P., Kazempour Dizaji, M., Gorji Bayani, P., Fahimi, F., Tabarsi, P., Velayati, A. (2016). Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 15(1), 247-252.
Majid Marjani; Parvaneh Baghaei; Mehdi Kazempour Dizaji; Pegah Gorji Bayani; Fanak Fahimi; Payam Tabarsi; Ali Akbar Velayati. "Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial". Iranian Journal of Pharmaceutical Research, 15, 1, 2016, 247-252.
Marjani, M., Baghaei, P., Kazempour Dizaji, M., Gorji Bayani, P., Fahimi, F., Tabarsi, P., Velayati, A. (2016). 'Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial', Iranian Journal of Pharmaceutical Research, 15(1), pp. 247-252.
Marjani, M., Baghaei, P., Kazempour Dizaji, M., Gorji Bayani, P., Fahimi, F., Tabarsi, P., Velayati, A. Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 2016; 15(1): 247-252.
Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
1Clinical Tuberculosis and Epidemiology Research Center
2Mycobacteriology Research Center
3Chronic Respiratory Diseases Research Center
4Clinical Tuberculosis and Epidemiology Research Cente
Abstract
Hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. This study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment. Trial registration: ANZCTR registration ID: ACTRN12610000621011.
Top